Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-05-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/1/e000798corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
by: Xin Sun, et al.
Published: (2020-05-01)

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial
by: Yu-Chun Zhu, et al.
Published: (2024-11-01)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
by: Qiang Liu, et al.
Published: (2020-05-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center
by: Jin-Xing Zhang, et al.
Published: (2022-01-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
by: Yinghui Xu, et al.
Published: (2023-02-01)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
by: Jun Fan, et al.
Published: (2021-11-01)

Long-term survival in metastatic gastric cancer patient with Apatinib plus S-1 maintenance treatment following first-line chemotherapy—case report
by: Zhen Wang, et al.
Published: (2024-11-01)

Correction: Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
Published: (2022-02-01)

Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
by: Ming Gao, et al.
Published: (2025-01-01)

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
by: Miao-Zhen Qiu, et al.
Published: (2024-12-01)

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
by: Zhonghua Zhao, et al.
Published: (2024-12-01)

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
by: Huimin Zou, et al.
Published: (2025-01-01)

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis
by: Guiyuan Xiang, et al.
Published: (2024-11-01)

Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trialResearch in context
by: Xiangyang Yu, et al.
Published: (2025-01-01)

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
by: Run-Cong Nie, et al.
Published: (2025-02-01)

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
by: Fan Sun, et al.
Published: (2024-12-01)

一种高精度改进型SHR基音检测算法
by: 应娜, et al.
Published: (2005-01-01)

Matilda, countess of the Perche (1171-1210): the expression of authority in name, style and seal
by: Kathleen Thompson
Published: (2003-07-01)

Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma
by: Dechao Zhan, et al.
Published: (2022-01-01)

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01)

Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo
by: Yanhao Ji, et al.
Published: (2024-11-01)

Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01)

Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024-12-01)

Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study
by: Tianzhi Wu, et al.
Published: (2024-12-01)

Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases: protocol of single-arm, open-label, phase II trial (Nab-PIPAC trial)
by: Di Giorgio Andrea, et al.
Published: (2024-11-01)

Retracted: Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma
by: Emergency Medicine International
Published: (2024-01-01)

P-glycoprotein-independent cytotoxic effects of 5-aminopyrazole in L1210 leukemia cells
by: Lucia Sofrankova, et al.
Published: (2025-04-01)

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
by: Jun Lu, et al.
Published: (2024-04-01)

Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial
by: Guoshuang Shen, et al.
Published: (2025-02-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial
by: Yuxi Chen, et al.
Published: (2024-12-01)

PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs
by: Katarzyna Dziubek, et al.
Published: (2024-12-01)

Evaluation of Selected Honey and One of Its Phenolic Constituent Eugenol against L1210 Lymphoid Leukemia
by: Saravana Kumar Jaganathan, et al.
Published: (2014-01-01)

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial
by: Junya Furukawa, et al.
Published: (2025-02-01)

SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity
by: Jun Zhang, et al.
Published: (2024-12-01)

Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
by: Ezhil Arasan Ramanan, et al.
Published: (2020-01-01)

Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
by: Gang Chen, et al.
Published: (2025-02-01)

Anemia Risk Prediction Model for Osteosarcoma Patients Post‐Chemotherapy Using Artificial Intelligence
by: Zhiping Su, et al.
Published: (2024-12-01)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Similar Items

Similar Items